Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ruslan Nuryyev"'
Autor:
Sandra Leibel, Rachael McVicar, Elizabeth Kwong, Alex Clark, Asuka Alvarado, Bethany Grimmig, Ruslan Nuryyev, Randee Young, Jamie Lee, Weiqi Peng, Yanfang Zhu, Eric Griffis, Cameron Nowell, Brian James, Suzie Alarcon, Atul Malhotra, Linden Gearing, Paul Hertzog, Cheska Galapate, Koen Galenkamp, Cosimo Commisso, Davey Smith, Xin Sun, Aaron Carlin, Ben Croker, Evan Snyder
The prevalence of “Long COVID”, including among vaccinated patients, is just one of the conundrums that indicate how much remains unknown about the lung’s response to viral infection, particularly to SARS-CoV-2 for which the lung is the point o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28bddc1c5bd9362825691124ddd8d327
https://doi.org/10.21203/rs.3.rs-2694520/v1
https://doi.org/10.21203/rs.3.rs-2694520/v1
Autor:
Sandra L. Leibel, Rachael N. McVicar, Rabi Murad, Elizabeth M. Kwong, Alex E. Clark, Asuka Alvarado, Bethany A. Grimmig, Ruslan Nuryyev, Randee E. Young, Jamie Casey Lee, Weiqi Peng, Yanfang Peipei Zhu, Eric Griffis, Cameron J. Nowell, Kang Liu, Brian James, Suzie Alarcon, Atul Malhotra, Linden J. Gearing, Paul J. Hertzog, Cheska Marie Galapate, Koen M.O. Galenkamp, Cosimo Commisso, Davey M. Smith, Xin Sun, Aaron F. Carlin, Ben A. Croker, Evan Y. Snyder
Publikováno v:
bioRxiv
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) causes an acute respiratory distress syndrome (ARDS) that resembles surfactant deficient RDS. Using a novel multi-cell type, human induced pluripotent stem cell (hiPSC)-derived lung organoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::176b7be3e6c03821db5f1393dae1180d
https://doi.org/10.1101/2023.01.26.525578
https://doi.org/10.1101/2023.01.26.525578
Autor:
Dustin R. Wakeman, Nirmalya Ghosh, Amy Plaia, Nejmi Dilmac, Walter D. Niles, Richard E. Hartman, Ruslan Nuryyev, Evan Y. Snyder, Neal H. Nathan, Melissa S. Dulcich, Alena Yusof, Richard L. Sidman, Beatriz Tone, Stephen Ashwal, Janessa B Law, Cameron D. Pernia, Andre Obenaus
Publikováno v:
Cell Reports. 31:107622
To date, no stem cell therapy has been directed to specific recipients-and, conversely, withheld from others-based on a clinical or molecular profile congruent with that cell's therapeutic mechanism-of-action (MOA) for that condition. We address this